Last year was one of the 'most event­ful in US biosim­i­lars his­to­ry,' but these an­a­lysts say 2022 should be 'a turn­ing point'

Though last year saw few­er mar­ket en­trants in the biosim­i­lar space than years past, Car­di­nal Health still called it one of the “most event­ful” in US biosim­i­lars his­to­ry, ac­knowl­edg­ing sev­er­al key ap­provals that have the po­ten­tial to make a big splash.

“This past year, the promise of biosim­i­lars has start­ed to be­come a re­al­i­ty, as greater com­pe­ti­tion for some of the costli­est bi­o­log­ic treat­ments on the mar­ket is be­gin­ning to dri­ve mean­ing­ful cost sav­ings,” So­nia Os­k­ouei, VP of biosim­i­lars at Car­di­nal, wrote in the com­pa­ny’s re­cent­ly re­leased re­port.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER